Dietary Supplement-Induced Hepatotoxicity: A Clinical Perspective

References

• Agarwal R, Diwanay S, Patki P, Patwardhan B. 1999. Studies on immunomodulatory activity of Withania somnifera (Ashwagandha) extracts in experimental immune inflammation. J Ethnopharmacol. 67(1):27–35. doi:10.1016/s0378-8741(99)00065-3.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Yuan W, Li S, Gupta SC. 2013. Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric. Mol Nutr Food Res. 57(9):1529–1542. doi:10.1002/mnfr.201200838.
   PubMed Web of Science ®Google Scholar
• Ahmad J, Odin JA, Hayashi PH, Fontana RJ, Conjeevaram H, Avula B, Khan IA, Barnhart H, Vuppalanchi R, Navarro VJ, et al. 2021. Liver injury associated with kratom, a popular opioid-like product: experience from the U.S. drug induced liver injury network. Drug Alcohol Depend. 218:108426. doi:10.1016/j.drugalcdep.2020.108426.
   PubMed Web of Science ®Google Scholar
• Akhgarjand C, Asoudeh F, Bagheri A, Kalantar Z, Vahabi Z, Shab-Bidar S, Rezvani H, Djafarian K. 2022. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 36(11):4115–4124. doi:10.1002/ptr.7598.
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, et al. 2005. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 129(2):512–521. doi:10.1016/j.gastro.2005.05.006.
   PubMed Web of Science ®Google Scholar
• Ashar BH, Rice TN, Sisson SD. 2007. Physicians’ understanding of the regulation of dietary supplements. Arch Intern Med. 167(9):966–969.
   PubMed Web of Science ®Google Scholar
• Avancini J, Maragno L, Santi CG, Criado PR. 2015. Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome: clinical features of 27 patients. Clin Exp Dermatol. 40(8):851–859. doi:10.1111/ced.12682.
   PubMed Web of Science ®Google Scholar
• Benichou C, Danan G, Flahault A. 1993. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J Clin Epidemiol. 46(11):1331–1336. doi:10.1016/0895-4356(93)90102-7.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. 2013. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology [Internet]. 144(7):1419. doi:10.1053/j.gastro.2013.02.006.
   PubMed Web of Science ®Google Scholar
• Björnsson HK, Björnsson ES, Avula B, Khan IA, Jonasson JG, Ghabril M, Hayashi PH, Navarro V. 2020. Liver injury due to ashwagandha. A case series from iceland and the U.S. Drug-induced liver injury network. Liver Int. 40(4):825–829. doi:10.1111/liv.14393.
   PubMed Web of Science ®Google Scholar
• Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, Fontana RJ, Ghabril MS, Barnhart H, Hoofnagle JH, et al. 2017. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 65(4):1267–1277. Apr 1 [cited 2024 Feb 8Available from:/pmc/articles/PMC5360519/ doi:10.1002/hep.28967.
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Reddy KR. 2013. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 37(1):3–17.
   PubMed Web of Science ®Google Scholar
• Calaquian LL, Yau I. 2022. Garcinia cambogia—A Supplement-Related Liver Injury. Cureus. 14(2):e22225.
   PubMed Web of Science ®Google Scholar
• CDC. 2013. Notes from the Field: Acute Hepatitis and Liver Failure Following the Use of a Dietary Supplement Intended for Weight Loss or Muscle Building—May–October. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6240a1.htm
   Google Scholar
• Chakraborty M, Fullerton AM, Semple K, Chea LS, Proctor WR, Bourdi M, Kleiner DE, Zeng X, Ryan PM, Dagur PK, et al. 2015. Drug-induced allergic hepatitis develops in mice when myeloid-derived suppressor cells are depleted prior to halothane treatment. Hepatology. 62(2):546–557. doi:10.1002/hep.27764.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, et al. 2015. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology. 148(7):1340–1352.e7. doi:10.1053/j.gastro.2015.03.006.
   PubMed Web of Science ®Google Scholar
• Cho T, Wang X, Yeung K, Cao Y, Uetrecht J. 2021. Liver injury caused by green tea extract in PD-1-/- Mice: An impaired immune tolerance model for idiosyncratic drug-induced liver Injury. Chem Res Toxicol. 34(3):849–856. Available fromhttps://pubmed.ncbi.nlm.nih.gov/33617238/. doi:10.1021/acs.chemrestox.0c00485.
   PubMed Web of Science ®Google Scholar
• Church RJ, Kullak-Ublick GA, Aubrecht J, Bonkovsky HL, Chalasani N, Fontana RJ, Goepfert JC, Hackman F, King NMP, Kirby S, et al. 2019. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology. 69(2):760–773. doi:10.1002/hep.29802.
   PubMed Web of Science ®Google Scholar
• Cirulli ET, Nicoletti P, Abramson K, Andrade RJ, Bjornsson ES, Chalasani N, Fontana RJ, Hallberg P, Li YJ, Lucena MI, et al. 2019. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology. 156(6):1707–1716.e2. doi:10.1053/j.gastro.2019.01.034.
   PubMed Web of Science ®Google Scholar
• Clemens MM, McGill MR, Apte U. 2019. Biomarkers of drug-induced liver injury. Adv Pharmacol. 85:241–262.
   PubMedGoogle Scholar
• Cohen PA. 2012. Assessing supplement safety—The FDA’s controversial proposal. N Engl J Med. 366(5):389–391.
   PubMed Web of Science ®Google Scholar
• CRS. 2007. Order Code RS22480 Updated Dietary Supplement and Nonprescription Drug Consumer Protection Act (P.L.109-462).
   Google Scholar
• Danan G, Benichou C. 1993. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol. 46(11):1323–1330. doi:10.1016/0895-4356(93)90101-6.
   PubMed Web of Science ®Google Scholar
• Danan G, Teschke R. 2023. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci [Internet]. 17(1):14–30.
   Google Scholar
• Data Brief 399. 2021. Dietary Supplement Use Among Adults: United States, 2017–2018. https://stacks.cdc.gov/view/cdc/101131
   Google Scholar
• de Boer YS, Sherker AH. 2017. Herbal and dietary supplement-induced liver injury. Clin Liver Dis. 21(1):135–149. https://pubmed.ncbi.nlm.nih.gov/27842768/.
   PubMed Web of Science ®Google Scholar
• Dickinson A, Blatman J, El-Dash N, Franco JC. 2014. Consumer usage and reasons for using dietary supplements: report of a series of surveys. J Am Coll Nutr. 33(2):176–182. doi:10.1080/07315724.2013.875423.
   PubMed Web of Science ®Google Scholar
• Dietary Supplements. 2024. FDA May Have Opportunities to Expand Its Use of Reported Health Problems to Oversee Products | U.S. GAO. https://www.gao.gov/products/gao-13-244
   Google Scholar
• FDA 2024a. Dietary Supplements | FDA. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements.
   Google Scholar
• FDA 2024c. DMAA in Products Marketed as Dietary Supplements. https://www.fda.gov/food/dietary-supplement-ingredient-directory/dmaa-products-marketed-dietary-supplements
   Google Scholar
• FDA. 2023a. Dietary Supplements. https://www.fda.gov/food/dietary-supplements.
   Google Scholar
• FDA. 2023b. MedWatch: The FDA Safety Information and Adverse Event Reporting Program | FDA. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
   Google Scholar
• FDA. 2024b. Dietary Supplement Labeling Guide. https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/dietary-supplement-labeling-guide.
   Google Scholar
• Fong T-L, Klontz KC, Canas-Coto A, Casper SJ, Durazo FA, Davern TJ, Hayashi P, Lee WM, Seeff LB. 2010. Hepatotoxicity due to hydroxycut®: A case series. Am J Gastroenterol. 105(7):1561–1566. Jul [cited 2023 Oct 30Available from:/pmc/articles/PMC3825455/ doi:10.1038/ajg.2010.5.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V. 2023. Mar 1 [ AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 77(3):1036–1065.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J, DILIN Study Group. 2009. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 32(1):55–68. doi:10.2165/00002018-200932010-00005.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, HHS. 2004. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule. Fed Regist. 69(28):6787–6854. https://pubmed.ncbi.nlm.nih.gov/14968803/
   PubMedGoogle Scholar
• Frieden TR, Harold Jaffe DW, Diaz PS, Moolenaar RL, Leahy MA, Martinroe JC, et al. 2013. Acute hepatitis and liver failure following the use of a dietary supplement intended for weight loss or muscle building—May–October 2013. Morbidity and Mortality Weekly Report. 62(40):817.
   PubMed Web of Science ®Google Scholar
• Fu S, Wu D, Jiang W, Li J, Long J, Jia C, Zhou T. 2019. Molecular biomarkers in drug-induced liver injury: challenges and future perspectives. Front Pharmacol. 10:1667. doi:10.3389/fphar.2019.01667.
   PubMed Web of Science ®Google Scholar
• Garcia-Alvarez A, Egan B, de Klein S, Dima L, Maggi FM, Isoniemi M, Ribas-Barba L, Raats MM, Meissner EM, Badea M, et al. 2014. Usage of plant food supplements across six European countries: findings from the PlantLIBRA consumer survey. PLoS One. 9(3):e92265. Available from: https://pubmed.ncbi.nlm.nih.gov/24642692/. doi:10.1371/journal.pone.0092265.
   PubMed Web of Science ®Google Scholar
• Geller AI, Shehab N, Weidle NJ, Lovegrove MC, Wolpert BJ, Timbo BB, Mozersky RP, Budnitz DS. 2015. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 373(16):1531–1540. doi:10.1056/NEJMsa1504267.
   PubMed Web of Science ®Google Scholar
• Gillessen A, Schmidt HHJ. 2020. Silymarin as supportive treatment in liver diseases: A narrative review. Adv Ther. 37(4):1279–1301. [cited 2023 Nov 15Available from:/pmc/articles/PMC7140758/ doi:10.1007/s12325-020-01251-y.
   PubMed Web of Science ®Google Scholar
• Grewal P, Ahmad J. 2019. Severe liver injury due to herbal and dietary supplements and the role of liver transplantation. World J Gastroenterol. 25(46):6704–6712.
   PubMed Web of Science ®Google Scholar
• Gu J, Tang S-J, Tan S-Y, Wu Q, Zhang X, Liu C-X, Gao X-S, Yuan B-D, Han L-J, Gao A-P, et al. 2015. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury. Int J Clin Exp Med. 8(3):4320–4327.
   PubMed Web of Science ®Google Scholar
• Guidance for Industry. 2023. Questions and Answers Regarding the Labeling of Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act | FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-regarding-labeling-dietary-supplements-required-dietary.
   Google Scholar
• Halegoua-DeMarzio D, Navarro V, Ahmad J, Avula B, Barnhart H, Barritt AS, Bonkovsky HL, Fontana RJ, Ghabril MS, Hoofnagle JH, et al. 2023. Liver injury associated with turmeric-a growing problem: ten cases from the drug-induced liver injury network [DILIN]. Am J Med. 136(2):200–206. doi:10.1016/j.amjmed.2022.09.026.
   PubMed Web of Science ®Google Scholar
• Hanatani T, Sai K, Tohkin M, Segawa K, Kimura M, Hori K, Kawakami J, Saito Y. 2014. Sep 1 [cited 2023 Nov 20 A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale. Pharmacoepidemiol Drug Saf. 23(9):984–988. doi:10.1002/pds.3603.
   PubMed Web of Science ®Google Scholar
• Hayashi PH, Lucena MI, Fontana RJ, Bjornsson ES, Aithal GP, Barnhart H, Gonzalez-Jimenez A, Yang Q, Gu J, Andrade RJ, et al. 2022. A revised electronic version of rucam for the diagnosis of drug induced liver injury. Hepatology. 76(1):18–31. doi:10.1002/hep.32327.
   PubMed Web of Science ®Google Scholar
• Herbalgram. 2023. US Sales of Herbal Supplements Increase by 9.7% in 2021. https://www.herbalgram.org/resources/herbalegram/volumes/volume-19/issue-11-november/news-and-features-1/2021-herb-market-report/.
   Google Scholar
• Hillman L, Gottfried M, Whitsett M, Rakela J, Schilsky M, Lee WM, Ganger D. 2016. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol. 111(7):958–965. doi:10.1038/ajg.2016.114.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Bonkovsky HL, Phillips EJ, Li Y-J, Ahmad J, Barnhart H, Durazo F, Fontana RJ, Gu J, Khan I, et al. 2021. HLA-B*35:01 and green tea induced liver injury. Hepatology. 73(6):2484–2493. Jun 1 [cited 2023 Nov 5Available from:/pmc/articles/PMC8052949/ doi:10.1002/hep.31538.
   PubMed Web of Science ®Google Scholar
• Hu J, Webster D, Cao J, Shao A. 2018. The safety of green tea and green tea extract consumption in adults – Results of a systematic review. Regul Toxicol Pharmacol. 95:412–433. doi:10.1016/j.yrtph.2018.03.019.
   PubMed Web of Science ®Google Scholar
• Incze M. 2019. Vitamins and Nutritional Supplements: What Do I Need to Know? JAMA Intern Med. 179(3):460–460.
   PubMed Web of Science ®Google Scholar
• Jing J, Teschke R. 2018. Traditional Chinese Medicine and Herb-induced Liver Injury: comparison with drug-induced liver injury. J Clin Transl Hepatol. 6(1):57–68. doi:10.14218/JCTH.2017.00033.
   PubMed Web of Science ®Google Scholar
• Johnston DI, Chang A, Viray M, Chatham-Stephens K, He H, Taylor E, Wong LL, Schier J, Martin C, Fabricant D, et al. 2016. Hepatotoxicity associated with the dietary supplement OxyELITE ProTM - Hawaii, 2013. Drug Test Anal. 8(3-4):319–327. doi:10.1002/dta.1894.
   PubMed Web of Science ®Google Scholar
• Jurgens TM, Whelan AM, Killian L, Doucette S, Kirk S, Foy E. 2012. Green tea for weight loss and weight maintenance in overweight or obese adults. Cochrane Database Syst Rev. 12(12):CD008650. doi:10.1002/14651858.CD008650.pub2.
   PubMedGoogle Scholar
• Kafrouni MI, Anders RA, Verma S. 2007. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Clin Gastroenterol Hepatol. 5(7):809–812.
   PubMed Web of Science ®Google Scholar
• Karkhanis J, Verna EC, Chang MS, Stravitz RT, Schilsky M, Lee WM, Brown RS. Acute Liver Failure Study Group. 2014. Steroid use in acute liver failure. Hepatology. 59(2):612–621. doi:10.1002/hep.26678.
   PubMed Web of Science ®Google Scholar
• Kennedy ET, Luo H, Houser RF. 2013. Dietary supplement use pattern of U.S. adult population in the 2007-2008 National Health and Nutrition Examination Survey (NHANES). Ecol Food Nutr. 52(1):76–84. https://pubmed.ncbi.nlm.nih.gov/23282192/. doi:10.1080/03670244.2012.706000.
   PubMed Web of Science ®Google Scholar
• Kratom. 2020. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. https://www.ncbi.nlm.nih.gov/books/NBK548231/.
   Google Scholar
• Krishnan PV, Feng ZZ, Gordon SC. 2009. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements. J Clin Gastroenterol. 43(7):672–675.
   PubMed Web of Science ®Google Scholar
• Kurien BT, Danda D, Scofield RH. 2015. Therapeutic potential of curcumin and curcumin analogues in rheumatology. Int J Rheum Dis. 18(6):591–593. doi:10.1111/1756-185X.12753.
   PubMed Web of Science ®Google Scholar
• Lang SM, Ortmann J, Rostig S, Schiffl H. 2019. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. Int J Mycobacteriol. 8(1):89–92. doi:10.4103/ijmy.ijmy_159_18.
   PubMed Web of Science ®Google Scholar
• Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TJ, Murray NG, McCashland T, Reisch JS, et al. 2009. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 137(3):856–864, 864.e1. [cited 2023 Nov 15Available fromhttps://pubmed.ncbi.nlm.nih.gov/19524577/. doi:10.1053/j.gastro.2009.06.006.
   PubMed Web of Science ®Google Scholar
• LIVERTOX. 2023. About LIVERTOX® - LiverTox - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK548196/
   Google Scholar
• Llewellyn HP, Vaidya VS, Wang Z, Peng Q, Hyde C, Potter D, Wang J, Zong Q, Arat S, Martin M, et al. 2021. Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans. Toxicol Sci. 181(1):23–34. doi:10.1093/toxsci/kfab003.
   PubMed Web of Science ®Google Scholar
• Lordan R. 2021. Dietary supplements and nutraceuticals market growth during the coronavirus pandemic – Implications for consumers and regulatory oversight. PharmaNutrition. 18:100282. doi:10.1016/j.phanu.2021.100282.
   PubMed Web of Science ®Google Scholar
• Luangchosiri C, Thakkinstian A, Chitphuk S, Stitchantrakul W, Petraksa S, Sobhonslidsuk A. 2015. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury. BMC Complement Altern Med. 15(1):334. doi:10.1186/s12906-015-0861-7.
   PubMed Web of Science ®Google Scholar
• Lubarska M, Hałasiński P, Hryhorowicz S, Mahadea DS, Łykowska-Szuber L, Eder P, Dobrowolska A, Krela-Kaźmierczak I. 2023. Liver dangers of herbal products: a case report of ashwagandha-induced liver injury. Int J Environ Res Public Health. 20(5) doi:10.3390/ijerph20053921.
   PubMedGoogle Scholar
• Mandlik DS, Namdeo AG. 2021. Pharmacological evaluation of Ashwagandha highlighting its healthcare claims, safety, and toxicity aspects. J Diet Suppl. 18(2):183–226. doi:10.1080/19390211.2020.1741484.
   PubMed Web of Science ®Google Scholar
• Maria VAJ, Victorino RMM. 1997. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 26(3):664–669 doi:10.1002/hep.510260319.
   PubMed Web of Science ®Google Scholar
• Mazzanti G, Di Sotto A, Vitalone A. 2015. Hepatotoxicity of green tea: an update. Arch Toxicol. 89(8):1175–1191.
   PubMed Web of Science ®Google Scholar
• Mazzanti G, Menniti-Ippolito F, Moro PA, Cassetti F, Raschetti R, Santuccio C, Mastrangelo S. 2009. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol. 65(4):331–341. doi:10.1007/s00228-008-0610-7.
   PubMed Web of Science ®Google Scholar
• McGill MR, Jaeschke H. 2019. Animal models of drug-induced liver injury. Biochim Biophys Acta Mol Basis Dis. 1865(5):1031–1039. doi:10.1016/j.bbadis.2018.08.037.
   PubMed Web of Science ®Google Scholar
• Memory Supplements. 2023. Clarifying FDA and FTC Roles Could Strengthen Oversight and Enhance Consumer Awareness | U.S. GAO. https://www.gao.gov/products/gao-17-416.
   Google Scholar
• Metushi IG, Hayes MA, Uetrecht J. 2015. Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology. 61(4):1332–1342. doi:10.1002/hep.27549.
   PubMed Web of Science ®Google Scholar
• Miousse IR, Skinner CM, Lin H, Ewing LE, Kosanke SD, Williams DK, Avula B, Khan IA, ElSohly MA, Gurley BJ, et al. 2017. Safety assessment of the dietary supplement OxyELITETM Pro (New Formula) in inbred and outbred mouse strains. Food Chem Toxicol. 109(Pt 1):194–209. doi:10.1016/j.fct.2017.08.025.
   PubMedGoogle Scholar
• Mishra S, Stierman B, Gahche JJ, Potischman N. 2021. Dietary supplement use among adults : United States, 2017–2018. NCHS Data Brief. 399:1–8. https://stacks.cdc.gov/view/cdc/101131.
   Google Scholar
• Navarro V, Avula B, Khan I, Verma M, Seeff L, Serrano J, Stolz A, Fontana R, Ahmad J. 2019. The contents of herbal and dietary supplements implicated in liver injury in the united states are frequently mislabeled. Hepatol Commun. 3(6):792–794. doi:10.1002/hep4.1346.
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Ahmad J, Barnhart H, Barritt AS, Bonkovsky H, Fontana RJ, et al. 2023. Characteristics & outcomes of liver injury due to herbal & dietary supplements in the u.s drug induced liver injury network. Boston, MA.
   Google Scholar
• Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, Reddy KR, Seeff LB, Serrano J, Sherker AH, et al. 2014. Liver injury from herbals and dietary supplements in the US drug induced liver injury network. Hepatology. 60(4):1399–1408. doi:10.1002/hep.27317.
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Bonkovsky HL, Hwang SI, Vega M, Barnhart H, Serrano J. 2013. Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci. 58(9):2682–2690. doi:10.1007/s10620-013-2687-9.
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. 2016. Liver Injury From Herbal and Dietary Supplements. https://search.usa.gov/search?-
   Google Scholar
• Niu H, Sanabria-Cabrera J, Alvarez-Alvarez I, Robles-Diaz M, Stankevičiūtė S, Aithal GP, Björnsson ES, Andrade RJ, Lucena MI. 2021. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacol Res. 164:105404. doi:10.1016/j.phrs.2020.105404.
   PubMed Web of Science ®Google Scholar
• Oketch-Rabah HA, Roe AL, Rider CV, Bonkovsky HL, Giancaspro GI, Navarro V, Paine MF, Betz JM, Marles RJ, Casper S, et al. 2020. United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. Toxicol Rep. 7:386–402. doi:10.1016/j.toxrep.2020.02.008.
   PubMed Web of Science ®Google Scholar
• Papp Z, Török L. 1999. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf [Internet]. 21(6):1665–1668.
   Web of Science ®Google Scholar
• Posadzki P, Watson LK, Alotaibi A, Ernst E. 2013. Prevalence of use of complementary and alternative medicine (CAM) by patients/consumers in the UK: systematic review of surveys. Clin Med (Lond). 13(2):126–131. doi:10.7861/clinmedicine.13-2-126.
   PubMed Web of Science ®Google Scholar
• Raina R, Verma PK, Taku I, Malik JK, Gupta RC. 2019. Garcinia Cambogia. In Nutraceuticals: Efficacy, Safety and Toxicity. Cambridge, MA: Academic Press. p. 975–990. https://www.ncbi.nlm.nih.gov/books/NBK548087/
   Google Scholar
• Rattis BAC, Ramos SG, Celes MRN. 2021. Curcumin as a potential treatment for COVID-19. Front Pharmacol. 12:675287.
   PubMed Web of Science ®Google Scholar
• Ravindra KC, Vaidya VS, Wang Z, Federspiel JD, Virgen-Slane R, Everley RA, Grove JI, Stephens C, Ocana MF, Robles-Díaz M, et al. 2023. Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans. Nat Commun. 14(1):1215. doi:10.1038/s41467-023-36858-6.
   PubMed Web of Science ®Google Scholar
• Regev A, Seeff LB, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, Watkins PB. 2014. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf. 37(Suppl 1):S47–S56. doi:10.1007/s40264-014-0185-4.
   PubMed Web of Science ®Google Scholar
• Richardson E, Akkas F, Cadwallader AB. 2022. What should dietary supplement oversight look like in the US? AMA J Ethics. 24(5):E402–E409. doi:10.1001/amajethics.2022.402.
   PubMedGoogle Scholar
• Robles-Díaz M, Nezic L, Vujic-Aleksic V, Björnsson ES. 2021. Role of ursodeoxycholic acid in treating and preventing idiosyncratic drug-induced liver injury. A systematic review. Front Pharmacol. 12:744488. Oct 27 [cited 2023 Nov 15Available from:/pmc/articles/PMC8578816/ doi:10.3389/fphar.2021.744488.
   PubMed Web of Science ®Google Scholar
• Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, McHutchison JG, Drug-Induced Liver Injury Network (DILIN). 2008. Reliability of the roussel uclaf causality assessment method for assessing causality in drug-induced liver injury. Hepatology. 48(4):1175–1183. doi:10.1002/hep.22442.
   PubMed Web of Science ®Google Scholar
• Roytman MM, Pörzgen P, Lee CL, Huddleston L, Kuo TT, Bryant-Greenwood P, Wong LL, Tsai N. 2014. Outbreak of severe hepatitis linked to weight-loss supplement OxyELITE pro. Am J Gastroenterol. 109(8):1296–1298.
   PubMed Web of Science ®Google Scholar
• Samavat H, Dostal AM, Wang R, Bedell S, Emory TH, Ursin G, Torkelson CJ, Gross MD, Le CT, Yu MC, et al. 2015The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: Study rationale, design, methods, and participant characteristics. Cancer Causes Control. 26(10):1405–1419. doi:10.1007/s10552-015-0632-2.
   PubMed Web of Science ®Google Scholar
• Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI, Low Dog T, et al. 2008. Safety of green tea extracts : a systematic review by the US Pharmacopeia. Drug Saf. 31(6):469–484. doi:10.2165/00002018-200831060-00003.
   PubMed Web of Science ®Google Scholar
• Shah NL, Zacharias I, Khettry U, Afdhal N, Gordon FD. 2008. Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases. Clin Gastroenterol Hepatol. 6(2):255–258. doi:10.1016/j.cgh.2007.11.010.
   PubMed Web of Science ®Google Scholar
• Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PSSR. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 64(4):353–356. doi:10.1055/s-2006-957450.
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Ahmed N, Goswami M, Chakrabarty A, Chowdhury G. 2021. DNA damage by Withanone as a potential cause of liver toxicity observed for herbal products of Withania somnifera (Ashwagandha). Curr Res Toxicol. 2:72–81. doi:10.1016/j.crtox.2021.02.002.
   PubMedGoogle Scholar
• Skinner CM, Miousse IR, Ewing LE, Sridharan V, Cao M, Lin H, Williams DK, Avula B, Haider S, Chittiboyina AG, et al. 2018. Dec 1 [cited 2024 Feb 8 Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE ProTM (New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments. Food Chem Toxicol. 122:21–32. doi:10.1016/j.fct.2018.09.067.
   PubMed Web of Science ®Google Scholar
• Solimini R, Rotolo MC, Mastrobattista L, Mortali C, Minutillo A, Pichini S, Pacifici R, Palmi I. 2017. Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping. Eur Rev Med Pharmacol Sci. 21 (1 Suppl):7–16. https://www.europeanreview.org/article/12427
   PubMedGoogle Scholar
• Stine JG, Lewis JH. 2016. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 10(4):517–536. doi:10.1586/17474124.2016.1127756.
   PubMed Web of Science ®Google Scholar
• Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, Baik GH, Kim JB, Kweon YO, Kim BI, et al. 2012. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 107(9):1380–1387. doi:10.1038/ajg.2012.138.
   PubMed Web of Science ®Google Scholar
• Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. 2009. Drug-induced liver injury in Japan: An analysis of 1676 cases between 1997 and 2006. Hepatol Res. 39(5):427–431. doi:10.1111/j.1872-034X.2008.00486.x.
   PubMed Web of Science ®Google Scholar
• Takikawa H, Takamori Y, Kumagi T, Onji M, Watanabe M, Shibuya A, Hisamochi A, Kumashiro R, Ito T, Mitsumoto Y, et al. 2003. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res. 27(3):192–195. doi:10.1016/s1386-6346(03)00232-8.
   PubMed Web of Science ®Google Scholar
• Tao L, Qu X, Zhang Y, Song Y, Zhang SX. 2019. Prophylactic therapy of silymarin (Milk Thistle) on antituberculosis drug-induced liver injury: a meta-analysis of randomized controlled trials. Can J Gastroenterol Hepatol. 2019:3192351. doi:10.1155/2019/3192351.
   PubMed Web of Science ®Google Scholar
• Tarn DM, Paterniti DA, Good JS, Coulter ID, Galliher JM, Kravitz RL, Karlamangla AS, Wenger NS. 2013. Physician-patient communication about dietary supplements. Patient Educ Couns. 91(3):287–294. doi:10.1016/j.pec.2013.01.021.
   PubMed Web of Science ®Google Scholar
• Teschke R, Danan G. 2020. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993–Mid 2020: a comprehensive analysis. Medicines. 7(10):62. doi:10.3390/medicines7100062.
   Google Scholar
• Teschke R, Eickhoff A. 2015. Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol. 6(MAR):72. doi:10.3389/fphar.2015.00072.
   PubMedGoogle Scholar
• Teschke R, Frenzel C, Schulze J, Eickhoff A. 2013. Herbal hepatotoxicity: Challenges and pitfalls of causality assessment methods. World J Gastroenterol. 19(19):2864–2882. doi:10.3748/wjg.v19.i19.2864.
   PubMed Web of Science ®Google Scholar
• United States Government Accountability Office. 2009. Report to Congressional Requesters DIETARY SUPPLEMENTS FDA Should Take Further Actions to Improve Oversight and Consumer Understanding.
   Google Scholar
• USDA. 2007. USDA Database for the Flavonoid Content of Selected Foods Release 2.1.
   Google Scholar
• Vaidya VS, Mehendale HM. 2018. Ephedra. In Encyclopedia of Toxicology. 3rd ed. Academic Press. p. 426–430. https://www.ncbi.nlm.nih.gov/books/NBK548711/.
   Google Scholar
• Vazquez JH, Clemens MM, Allard FD, Yee EU, Kennon-McGill S, Mackintosh SG, Jaeschke H, Hambuchen MD, McGill MR. 2020. Identification of serum biomarkers to distinguish hazardous and benign aminotransferase elevations. Toxicol Sci. 173(2):244–254. doi:10.1093/toxsci/kfz222.
   PubMed Web of Science ®Google Scholar
• Vazquez JH, McGill MR. 2021. Redrawing the map to novel DILI biomarkers in circulation: Where are we, where should we go, and how can we get there? Livers [Internet]. 1(4):286–293. doi:10.3390/livers1040022.
   PubMedGoogle Scholar
• Ventola CL. 2010. Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States: Part 1: The Widespread Use of CAM and the Need for Better-Informed Health Care Professionals to Provide Patient Counseling. P T. 35(8):461–468.
   PubMedGoogle Scholar
• Vuppalanchi R, Bonkovsky HL, Ahmad J, Barnhart H, Durazo F, Fontana RJ, Gu J, Khan I, Kleiner DE, Koh C, et al. 2022. Garcinia Cambogia, either alone or in combination with green tea causes moderate to severe liver injury. Clin Gastroenterol Hepatol. 20(6):e1416–e1425. doi:10.1016/j.cgh.2021.08.015.
   PubMed Web of Science ®Google Scholar
• Wai C-T, Tan B-H, Chan C-L, Sutedja DS, Lee Y-M, Khor C, Lim S-G. 2007. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 27(4):465–474. doi:10.1111/j.1478-3231.2007.01461.x.
   PubMed Web of Science ®Google Scholar
• Wallace TC. 2015. Twenty years of the dietary supplement health and education act—how should dietary supplements be regulated? J Nutr. 145(8):1683–1686. doi:10.3945/jn.115.211102.
   PubMed Web of Science ®Google Scholar
• Warning Letters. 2024. FDA https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
   Google Scholar
• Willson C. 2018. Dietary Supplements Containing Aegeline and DMAA (1,3-Dimethylamylamine) and their Role in Liver Injury. Inter J Med Res Health Sci. 7(7):10–35. www.ijmrhs.com
   Google Scholar
• Winslow LC, Shapiro H. 2002. Physicians want education about complementary and alternative medicine to enhance communication with their patients. Arch Intern Med. 162(10):1176–1181. doi:10.1001/archinte.162.10.1176.
   PubMedGoogle Scholar
• Wolfram S, Wang Y, Thielecke F. 2006. Anti-obesity effects of green tea: from bedside to bench. Mol Nutr Food Res. 50(2):176–187. doi:10.1002/mnfr.200500102.
   PubMed Web of Science ®Google Scholar
• Wong LL, Lacar L, Roytman M, Orloff SL. 2017. Urgent liver transplantation for dietary supplements: an under-recognized problem. Transplant Proc. 49(2):322–325. doi:10.1016/j.transproceed.2016.11.041.
   PubMed Web of Science ®Google Scholar
• Younes M, Aggett P, Aguilar F, Crebelli R, Dusemund B, Filipič M, Frutos MJ, Galtier P, Gott D, Gundert-Remy U, et al. 2018. Scientific opinion on the safety of green tea catechins. Efsa J. 16(4):e05239. Apr 1 [cited 2023 Nov 5Available from:/pmc/articles/PMC7009618/ doi:10.2903/j.efsa.2018.5239.
   PubMed Web of Science ®Google Scholar
• Yu Z, Samavat H, Dostal AM, Wang R, Torkelson CJ, Yang CS, Butler LM, Kensler TW, Wu AH, Kurzer MS, et al. 2017. Effect of green tea supplements on liver enzyme elevation: results from a randomized intervention study in the United States. Cancer Prev Res. 10(10):571–579. doi:10.1158/1940-6207.CAPR-17-0160.
   PubMed Web of Science ®Google Scholar
• Zheng E, Navarro VJ. 2017. Causality assessment for liver injury attributable to dietary supplements. Clin Liver Dis (Hoboken). 9(3):60–62. doi:10.1002/cld.618.
   PubMedGoogle Scholar
• Zheng E, Sandhu N, Navarro V. 2020. Drug-induced liver injury secondary to herbal and dietary supplements. Clin Liver Dis. 24(1):141–155. doi:10.1016/j.cld.2019.09.009.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H. 2013. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol. 25(7):825–829. doi:10.1097/MEG.0b013e32835f6889.
   PubMed Web of Science ®Google Scholar